Tel: +44(0)20 7691 0984 Email: Newsletter Sign Up
  • CEO Mark Duxon interviewed by The Pharma Letter on impact of Brexit on CROs...
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • State-of-the-art premises opening this month at Discovery Park in Kent...
  • Newly published work in Frontiers in Psychiatry demonstrating
  • the effectiveness of a clinically relevant dose of ketamine...
  • Head to 2021 conferences page to see titles of abstracts...


All the latest conference updates; those that we are attending and the studies that we are presenting

IASP Virtual Series horizontal 1200px

As experts in preclinical neuroscience, we look forward to attending the 25th annual international congress of the World Muscle Society and making contact with other participants. Already involved in the EU-funded Brain Involvement in Dystrophinopathies, (BIND) project, our combined research aims at achieving ground-breaking progress in the understanding and treatment of neuropsychiatric comorbidities affecting Duchenne and Becker muscular dystrophy patients. For more information about our work in this particular field please email This email address is being protected from spambots. You need JavaScript enabled to view it.


Start a Conversation

uk flag+44 (0)20 7691 0984

ireland flag+353 (0)1896 42 60

poland flag+48 515 244 120



Copyright © 2021 Transpharmation Ltd. All Rights Reserved.

Copyright © 2019 Transpharmation Ltd. All Rights Reserved. Website created by Identity Ipswich Web Design